Abstract
The unprecedented disruption of the COVID-19 pandemic raises crucial questions about its impact on chronic pain levels in the US population. We present a comprehensive analysis of chronic pain (CP), high-impact chronic pain (HICP), and site-specific pain prevalence before, during, and after the pandemic, and investigate key contributing factors. We analyze a nationally representative sample of 90,769 community-dwelling adults aged 18 years and older from 3 cross-sectional waves of the National Health Interview Survey (2019, 2021, and 2023). Outcomes are CP and HICP; we also present findings for 6 site-specific pain measures. We include an extensive range of covariates (demographics, socioeconomic status, health behaviors, health conditions, mental health, and health insurance type); additional analyses also explore the role of long COVID. Chronic pain prevalence increased from 20.5% (95% confidence interval: 19.9%-21.2%) in 2019 to 20.9% (20.3%-21.6%) in 2021 and 24.3% (23.7%-25.0%) in 2023, representing an 18% increase over the study period. High-impact chronic pain prevalence, which was 7.5% (7.1%-7.8%) in 2019, declined to 6.9% (6.6%-7.3%) in 2021 before rising to 8.5% (8.1%-8.9%) in 2023, a 13% overall increase. The 2023 pain increases were widespread: they occurred for all examined body sites except tooth/jaw pain and all population subgroups. Long COVID accounted for approximately 13% of the observed 2019 to 2023 increase in both CP and HICP. In 2023, an estimated 60 million Americans experienced CP and 21 million experienced HICP, the highest prevalence ever recorded in the National Health Interview Survey. These findings suggest a significant escalation in the population burden of pain, with crucial implications for public health policy.